Sanofi stock (FR0000127771): Q1 earnings beat on Dupixent strength

Sanofi reported first-quarter 2026 results on April 25, 2026, posting revenue of €9.29 billion, up 10.7% at constant exchange rates compared to the prior year period, according to Sanofi investor relations as of 04/25/2026. The multinational pharmaceutical company's performance was fueled by strong sales of Dupixent and other immunology products, signaling continued momentum in its core therapeutic areas.

Dupixent, co-developed with Regeneron, remains Sanofi's top earner, posting €3.5 billion in Q1 2026 sales, a 25% increase year-over-year, driven by new indications in chronic obstructive pulmonary disease (COPD) and asthma. Vaccines contributed €1.8 billion, led by Beyfortus for respiratory syncytial virus (RSV) prevention. Rare disease drugs like Xenpozyme added momentum with recent launches, demonstrating diversification across the company's portfolio.

As of: May 11, 2026

By the editorial team – specialized in equity coverage.

Sanofi: core business model

Sanofi is a multinational pharmaceutical company that researches, develops, manufactures, and markets prescription medicines, vaccines, and consumer healthcare products worldwide. Headquartered in France with a market capitalization of $105.63 billion, the company operates across immunology, neurology, oncology, and rare disease segments. For US investors, Sanofi trades on Nasdaq under the ticker SNY, providing direct exposure to a diversified global biopharma portfolio with significant revenue generation from the American market.

Main revenue and product drivers for Sanofi

Dupixent dominates Sanofi's revenue stream, accounting for €3.5 billion in Q1 2026 sales with a 25% year-over-year increase. The drug treats atopic dermatitis, asthma, and COPD, with ongoing clinical trials expanding its indication portfolio. Vaccines, particularly Beyfortus for RSV prevention, generated €1.8 billion in Q1 revenue. Rare disease medications and consumer healthcare products round out the portfolio, providing revenue stability and growth optionality across multiple therapeutic areas.

Conclusion

Sanofi's Q1 2026 earnings demonstrate solid execution across its core therapeutic areas, with Dupixent's continued expansion and vaccine portfolio growth supporting revenue momentum. The company's dual listing on Euronext Paris and Nasdaq provides US investors with convenient access to a diversified global pharmaceutical player. While the stock has declined 10.6% year-to-date amid broader market dynamics, the underlying business fundamentals remain supported by blockbuster drug performance and pipeline advancement.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.